financetom
Business
financetom
/
Business
/
Sempra posts higher Q2 profit on record-high temperatures
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sempra posts higher Q2 profit on record-high temperatures
Aug 6, 2024 7:26 AM

(Reuters) - U.S. utility Sempra ( SRE ) posted a rise in second-quarter profit on Tuesday, as it benefited from strong demand for electricity during the peak summer months.

The utility benefited from an increase in demand as customers cranked up their cooling appliances such as air conditioners and fridges to deal with the hot temperatures during the quarter.

According to scientists, 2024 could outrank 2023 as the hottest year since records began, after human-caused climate change and El Nino natural weather phenomenon both pushed temperatures to record highs in the year so far.

Sempra Infrastructure - the company's unit that develops, invests and operates clean energy technologies like carbon sequestration and clean hydrogen - reported quarterly earnings of $291 million, compared with $208 million last year.

Companies like Sempra ( SRE ), which operates clean energy technologies, are expected to benefit from the U.S. government's push for big technology firms to invest in new climate-friendly energy generation to cater to surging AI power needs.

The company, which supplies electricity and natural gas to nearly 40 million customers in parts of California, Texas and Mexico, said revenue from electric utilities came in at $1.14 billion in the second quarter, up from $1.05 billion last year.

However, Sempra ( SRE ) missed adjusted profit and revenue estimates for the quarter. It posted an adjusted profit of 89 cents per share, below estimates of 94 cents per share, according to LSEG data.

The company's quarterly total revenue fell nearly 10% to $3.01 billion, also missing estimates of $3.4 billion.

The San Diego, California-based company's net income rose to $713 million, or $1.12 per share, in the second quarter, from $603 million, 95 cents per share, last year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved